Show simple item record

dc.contributor.authorJuan, O
dc.contributor.authorPopat, S
dc.date.accessioned2018-02-19T11:10:06Z
dc.date.issued2017-03
dc.identifier.citationTherapeutic advances in medical oncology, 2017, 9 (3), pp. 201 - 216
dc.identifier.issn1758-8340
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/1279
dc.identifier.eissn1758-8359
dc.identifier.doi10.1177/1758834016687262
dc.description.abstractDiscovery of sensitizing mutations in epidermal growth factor receptor ( EGFR) and the subsequent development of EGFR tyrosine kinase inhibitors (TKIs) have substantially changed the treatment of lung cancer. First-line treatment with EGFR TKIs (gefitinib, erlotinib and afatinib) has demonstrated a superior response rate and progression-free survival (PFS) compared with chemotherapy in EGFR -mutation positive patients. However, a number of open questions remain, such as choice between the three EGFR TKIs licensed, treatment of patients unsuitable for chemotherapy due to morbidity or advanced age, management of acquired resistance and optimal biological sample to determine EGFR status. Recently the first head-to-head trial comparing gefitinib and afatinib (LUX-Lung 7) has been reported. Moreover, third-generation EGFR TKIs such as osimertinib, rociletinib, olmutinib and ASP8273, with preferential activity against T790M mutant tumours, the commonest resistance mechanism to EGFR TKIs, have shown promising results in early clinical trials, with osimertinib now licensed. In this review, we summarize latest advances in the treatment of EGFR -mutation positive patients focusing on controversial areas and emerging challenges to optimally treat these patients in the future.
dc.formatPrint-Electronic
dc.format.extent201 - 216
dc.languageeng
dc.language.isoeng
dc.titleTreatment choice in epidermal growth factor receptor mutation-positive non-small cell lung carcinoma: latest evidence and clinical implications.
dc.typeJournal Article
dcterms.dateAccepted2016-11-09
rioxxterms.versionofrecord10.1177/1758834016687262
rioxxterms.licenseref.startdate2017-03
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfTherapeutic advances in medical oncology
pubs.issue3
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Thoracic Oncology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Thoracic Oncology/Thoracic Oncology (hon.)
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Thoracic Oncology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Thoracic Oncology/Thoracic Oncology (hon.)
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.publication-statusPublished
pubs.volume9
pubs.embargo.termsNot known
icr.researchteamThoracic Oncologyen_US
dc.contributor.icrauthorPopat, Sanjayen
dc.contributor.icrauthorMarsden,en


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record